Loading...
•
Mar 31, 2024
Amicus Therapeutics Q1 2024 Earnings Report
Amicus Therapeutics reported a strong start to the year with excellent commercial performance and significant total revenue growth.
Key Takeaways
Amicus Therapeutics announced its Q1 2024 financial results, highlighting a 28% year-over-year increase in total revenue, reaching $110.4 million. The company is raising its full-year 2024 Galafold guidance and is pleased with the strong commercial launch of Pombiliti and Opfolda. Amicus reiterates its full-year non-GAAP profitability projection for 2024.
Total revenue for Q1 2024 reached $110.4 million, a 28% increase year-over-year.
The company is guiding to full-year 2024 total revenue growth of 25%-30% at CER.
Full-year 2024 Galafold guidance was raised due to continued strong demand.
Pombiliti and Opfolda experienced a strong commercial launch with an increasing rate of commercial patient starts.
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics Revenue by Segment
Revenue by Segment
Galafold Revenue
CapyFin.comPombiliti + Opfolda Revenue
CapyFin.com Forward Guidance
Amicus is focused on key strategic priorities in 2024, expecting significant total revenue growth and full year non-GAAP profitability.
Revenue & Expenses
Visualization of income flow from segment revenue to net income